Robyn D Gartrell

Learn More
BACKGROUND Studies have shown racial differences in cancer outcomes. We investigate whether survival differences existed in Hispanic patients with glioblastoma (GBM) compared with other ethnicities from our modern radiotherapy series, because no study to date has focused on outcomes in this group after radiation therapy. METHODS We retrospectively(More)
Medulloblastoma (MDB) represents a major form of malignant brain tumors in the pediatric population. A vast spectrum of research on MDB has advanced our understanding of the underlying mechanism, however, a significant need still exists to develop novel therapeutics on the basis of gaining new knowledge about the characteristics of cell signaling networks(More)
4005. P299<lb>Phosphopeptides as novel tumor antigens in colorectal cancer<lb>Sarah A Penny, Jennifer G Abelin, Abu Z Saeed, Stacy A Malaker,<lb>Paisley T Myers, Jeffrey Shabanowitz, Stephen T Ward, Donald F<lb>Hunt, Mark Cobbold<lb>University of Birmingham, Birmingham, England, UK; University of<lb>Virginia, Charlottesville, VA, USA; Stanford University,(More)
4501. Coinhibition & Costimulation O4 Computational identification, functional characterization, and antibody blockade of a new immune checkpoint in the TIGIT family of interacting molecules Ofer Levy, Christopher Chan, Gady Cojocaru, Spencer Liang, Eran Ophir, Sudipto Ganguly, Amir Toporik, Maya Kotturi, Tal Fridman Kfir, Benjamin M. Murter, Kathryn(More)
Talimogene laherparepvec (T-Vec) is the first live virus to be approved by the US Food and Drug Administration for the treatment of cancer. This engineered version of herpes simplex virus type 1 (HSV-1) is the product of decades of preclinical work aimed at identifying and modifying aspects of the viral genome involved in virulence and immunogenicity. T-Vec(More)
BACKGROUND To date, patients with pre-existing autoimmune conditions have been excluded from immunotherapy trials out of concern for severe autoimmune exacerbations. CASE PRESENTATION We describe the first case of a patient with metastatic cKIT mutated acral melanoma, brain metastasis, and pre-existing severe autoimmune bullous pemphigoid (BP) with stable(More)
Methods TCGA dataset for melanoma (n=407) was screened to determine two extreme groups of patients – alive at least 4 years (n=67) and dead within 2 years from diagnosis (n=59). Genome wide differential expression analysis was performed between the two groups to study our prognostic signature. We used gene set enrichment analysis (GSEA) to evaluate the(More)
PURPOSE Adjuvant hypofractionated radiation therapy (HRT) for elderly patients with newly diagnosed glioblastoma (GBM) is a reasonable option compared with standard fractionation radiation therapy (SFRT). Outcomes in patients receiving HRT in the presence of temozolomide (TMZ) compared with SFRT with TMZ are unclear. We examined HRT for GBM with TMZ in(More)
BACKGROUND The standard of care for patients with newly diagnosed glioblastoma (GBM) is maximal safe resection followed by adjuvant radiation therapy (RT) and temozolomide (TMZ). OBJECTIVE To investigate whether the timing of adjuvant RT after surgery affected outcome in patients with GBM. METHODS We retrospectively reviewed all patients with a(More)
  • 1